Abstract
Background: The metabolic syndrome (MetS) has been found to be closely related with thrombotic diseases. The mechanism, however, is far from elucidated. Aim: This study was designed to investigate the relationship between endogenous resistin and thrombosis mediating factors, as well as its potential effects on the gene expression of cardiovascular disease biomarkers. Methods: Ninety patients satisfied the MetS criteria, and 55 healthy subjects were recruited as part of a single-center clinical study. Plasma levels of resistin, tissue factor (TF), tissue factor pathway inhibitor (TFPI), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) were measured by enzyme-linked immunosorbent assays. The effect of resistin on the expression of cardiovascular disease biomarkers in human umbilical vein endothelial cells (HUVEC) was assayed by gene microarray. Results: 1) The average levels of resistin in MetS patients with or without acute myocardial or cerebral infarction were significantly higher than those of the controls. 2) The TF and TFPI increase was higher in MetS with infarction patients than in MetS patients. 3) In MetS with infarction patients, resistin was positively correlated with TF and PAI-1 (r=0.313, p=0.008; r=0.401, p=0.002, respectively). 4) In HUVEC, the microarray showed that apolipoprotein C-I, ACE, tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) and member 5 (CD40) genes expression were dramatically increased by resistin. Conclusion: In patients with MetS, resistin is strongly associated with hypercoagulative and hypofibrinolitic activities. Moreover, resistin may induce thrombotic complications via mediating the lipoprotein metabolism and stimulating inflammation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008, 29: 777–822.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365: 1415–28.
Bataille V, Perret B, Dallongeville J, et al. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort. Diabetes Metab 2006, 32: 475–9.
Simons LA, Simons J, Friedlander Y, McCallum J. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study. Med J Aust 2007, 186: 400–3.
Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28: 857–64.
Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006, 69: 76–85.
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001, 409: 307–12.
Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007, 156: 279–84.
Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metablic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 2008, 69: 74–80.
Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51: 534–9.
Ohmori R, Momiyama Y, Kato R, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46: 379–80.
Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13: 1764–71.
Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111: 932–9.
Iqbal N, Seshadri P, Stern L, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005, 9: 161–5.
Filippidis G, Liakopoulos V, Mertens PR, et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif 2005, 23: 421–8.
Esmon CT. The regulation of natural anticoagulant pathways. Science 1987, 235: 1348–52.
Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991, 66: 6–15.
Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984, 108: 150–8.
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366: 1059–62.
Jin H, Qiu WB, Mei YF, et al. Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor down-regulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J Androl 2009,11: 266–71.
Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110: 1245–50.
Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality—results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007, 262: 113–22.
Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 2007, 92: 374–80.
Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008, 93: 3165–72.
Qi Q, Wang J, Li H, et al. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008, 159: 585–93.
Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193: 121–8.
Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008, 93: 2647–53.
Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002, 106: 2442–7.
DelGiudice LA, White GA. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. J Vet Emerg Crit Care (San Antonio) 2009, 19: 23–9.
Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000, 20: 1362–73.
Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009, 35: 468–77.
Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008, 57: 494–501.
de Haan W, Out R, Berbée JF, et al. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem Biophys Res Commun 2008, 377: 1294–8.
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54: 669–77.
Author information
Authors and Affiliations
Corresponding authors
Additional information
These authors contributed equally to the paper.
Rights and permissions
About this article
Cite this article
Fang, W.Q., Zhang, Q., Peng, Y.B. et al. Resistin levelispositively correlated with thrombotic complications in Southern Chinese metabolic syndrome patients. J Endocrinol Invest 34, e36–e42 (2011). https://doi.org/10.1007/BF03347059
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347059